Allogene Therapeutics Inc (NASDAQ:ALLO) shares, rose in value, with the stock price down by -0.98% to the previous day’s close as strong demand from buyers drove the stock to $4.05.
Actively observing the price movement in the last trading, the stock closed the session at $4.09. The value of beta (5-year monthly) was 0.81. Referring to stock’s 52-week performance, its high was $6.89, and the low was $2.23. On the whole, ALLO has fluctuated by -25.00% over the past month.
With the market capitalization of Allogene Therapeutics Inc currently standing at about $684.81 million, investors are eagerly awaiting this quarter’s results, scheduled for May 01, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.41, which is expected to increase to -$0.23 for fiscal year -$1.66 and then to about -$1.54 by fiscal year 2025. Data indicates that the EPS growth is expected to be 20.60% in 2025, while the next year’s EPS growth is forecast to be 7.20%.
According to the average forecast, sales growth in current quarter could jump down -80.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $40k, representing a decrease of -57.90% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ALLO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ALLO currently trading nearly -12.05% and -8.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.60, while the 7-day volatility ratio is showing 4.63% which for the 30-day chart, stands at 7.45%. Furthermore, Allogene Therapeutics Inc (ALLO)’s beta value is 0.81, and its average true range (ATR) is 0.32.
A comparison of Allogene Therapeutics Inc (ALLO) with its peers suggests the former has fared considerably weaker in the market. ALLO showed an intraday change of -0.98% in last session, and over the past year, it shrunk by -20.43%%.
Data on historical trading for Allogene Therapeutics Inc (NASDAQ:ALLO) indicates that the trading volumes over the past 10 days have averaged 1.59 million and over the past 3 months, they’ve averaged 2.68 million. According to company’s latest data on outstanding shares, there are 169.09 million shares outstanding.
Nearly 38.25% of Allogene Therapeutics Inc’s shares belong to company insiders and institutional investors own 60.84% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 27.75 million shares as on Mar 15, 2024, resulting in a short ratio of 10.12. According to the data, the short interest in Allogene Therapeutics Inc (ALLO) stood at 16.41% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 23.45 million. The stock has risen by 26.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALLO stock heading into the next quarter.
